Audentes Therapeutics (BOLD)

22.89 -0.05 (0.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (3/8/19 *Est.)

Latest Headlines

Form 4 Audentes Therapeutics, For: Dec 06 Filed by: Patterson Matthew R December 10, 2018 4:40 PM - SEC Filing Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 7, 2018 6:00 PM - PR NewsWire JPMorgan Starts Audentes Therapeutics (BOLD) at Overweight November 26, 2018 3:52 AM - StreetInsider Form 4 Audentes Therapeutics, For: Nov 15 Filed by: NEWMAN MARY November 16, 2018 6:42 PM - SEC Filing Form 4 Audentes Therapeutics, For: Nov 15 Filed by: PRASAD SUYASH November 16, 2018 6:38 PM - SEC Filing Form 4 Audentes Therapeutics, For: Nov 15 Filed by: LANGE LOUIS G November 16, 2018 6:35 PM - SEC Filing Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 November 14, 2018 4:55 PM - StreetInsider Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, K November 9, 2018 8:55 AM - Globe NewsWire Audentes Therapeutics to Participate in Upcoming Investor Conferences November 7, 2018 8:00 AM - PR NewsWire Form 10-Q Audentes Therapeutics, For: Sep 30 November 7, 2018 6:21 AM - SEC Filing William Blair Downgrades Audentes Therapeutics (BOLD) to Market Perform November 7, 2018 5:10 AM - StreetInsider Audentes Therapeutics (BOLD) PT Lowered to $41 at Piper Jaffray November 7, 2018 4:34 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $21 at B.Riley/FBR November 7, 2018 3:45 AM - StreetInsider Form S-8 Audentes Therapeutics, November 6, 2018 5:31 PM - SEC Filing Form 8-K Audentes Therapeutics, For: Nov 05 November 6, 2018 4:53 PM - SEC Filing Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c November 6, 2018 4:46 PM - StreetInsider Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update November 6, 2018 4:01 PM - PR NewsWire Audentes Therapeutics (BOLD) Announces Co-Founder & CEO Matthew R. Patterson as Chairman November 5, 2018 8:08 AM - StreetInsider Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman November 5, 2018 8:00 AM - PR NewsWire Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018 October 30, 2018 8:00 AM - PR NewsWire Form SC 13G Audentes Therapeutics, Filed by: Partner Fund Management, L.P. October 29, 2018 4:09 PM - SEC Filing Form 8-K Audentes Therapeutics, For: Oct 09 October 11, 2018 4:25 PM - SEC Filing Form 424B5 Audentes Therapeutics, October 11, 2018 4:16 PM - SEC Filing Audentes Therapeutics (BOLD) Prices 5.2M Share Common Offering at $29/Sh October 11, 2018 6:07 AM - StreetInsider Audentes Therapeutics Announces Pricing of Public Offering of Common Stock October 10, 2018 8:30 PM - PR NewsWire Form SC 13G/A Audentes Therapeutics, Filed by: FMR LLC October 10, 2018 10:05 AM - SEC Filing Form 424B5 Audentes Therapeutics, October 9, 2018 4:29 PM - SEC Filing Audentes Therapeutics (BOLD) Plans $150M Offering of Common Stock October 9, 2018 4:20 PM - StreetInsider Audentes Therapeutics Announces Proposed Public Offering of Common Stock October 9, 2018 4:20 PM - PR NewsWire Guggenheim Starts Audentes Therapeutics (BOLD) at Neutral October 9, 2018 4:13 PM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $52 at Wedbush October 8, 2018 6:33 AM - StreetInsider Form 8-K Audentes Therapeutics, For: Oct 05 October 5, 2018 8:06 AM - SEC Filing Audentes Therapeutics (BOLD) Highlights New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy October 5, 2018 8:03 AM - StreetInsider Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annua October 5, 2018 8:01 AM - PR NewsWire Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the October 5, 2018 8:00 AM - PR NewsWire Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine October 3, 2018 9:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Oct 01 Filed by: PRASAD SUYASH October 2, 2018 7:06 PM - SEC Filing Form 4 Audentes Therapeutics, For: Oct 01 Filed by: Patterson Matthew R October 2, 2018 7:04 PM - SEC Filing Form 4 Audentes Therapeutics, For: Sep 28 Filed by: GRAY JOHN T. October 2, 2018 7:04 PM - SEC Filing Form 4 Audentes Therapeutics, For: Sep 24 Filed by: LANGE LOUIS G September 26, 2018 7:01 PM - SEC Filing Audentes Therapeutics to Participate in Upcoming Investor Conferences September 26, 2018 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Sep 24 Filed by: Patterson Matthew R September 24, 2018 6:14 PM - SEC Filing Audentes Therapeutics (BOLD) to Present New Data from ASPIRO at WMS September 24, 2018 8:05 AM - StreetInsider Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Socie September 24, 2018 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Sep 18 Filed by: Patterson Matthew R September 20, 2018 7:02 PM - SEC Filing Full Article List